Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment

Drugs and Aging

Volumn 10, Issue 5, 1997, Pages 367-383

  Young, B Kay ^a   Camicioli, Richard ^a   Ganzini, Linda ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; APOMORPHINE; BENZATROPINE; BROMOCRIPTINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DIPHENHYDRAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; MIANSERIN; MONOAMINE OXIDASE B INHIBITOR; ONDANSETRON; PERGOLIDE; PIRIBEDIL; PROCYCLIDINE; PROFENAMINE; REMOXIPRIDE; RISPERIDONE; SELEGILINE; SEROTONIN ANTAGONIST; THIORIDAZINE; TRIHEXYPHENIDYL; ZOTEPINE;

AGRANULOCYTOSIS; ANXIETY NEUROSIS; APLASTIC ANEMIA; CLINICAL FEATURE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DELIRIUM; DELUSION; DEMENTIA; DRUG COST; DRUG HYPERSENSITIVITY; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; JEALOUSY; MANIA; MENTAL DISEASE; MOTOR PERFORMANCE; NEUROLOGIC DISEASE; NEUROPSYCHIATRY; ORAL DRUG ADMINISTRATION; PANIC; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SEIZURE; SLEEP DISORDER; VISUAL HALLUCINATION;

EID: 0030983603     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199710050-00005     Document Type: Review

References (153)

1. Cummings JL. Behavioral complications of drug treatment of Parkinson's disease. J Am Geriatr Soc 1991; 39: 708-16
2. Chaná P, Weiser R, Jiménez J, et al. Origin of psychiatric complications in Parkinson's disease [abstract]. Mov Disord 1994; 9 Suppl. 1: 59
3. Sanchez-Ramos JR, Ortoll R, Singer C, et al. Visual hallucinations in Parkinson's disease. Ann Neurol 1993; 34 (2): 264-5
4. Haeske-Dewick HC. Hallucinations in Parkinson's disease: characteristics and associated clinical features. Int J Geriatr Psychiatry 1995; 10: 487-95
5. Stein MB, Heuser IJ, Juncos JL, et al. Anxiety disorders in patients with Parkinson's disease. Am J Psychiatry 1990; 147: 217-20
6. Nausieda PA, Glantz R, Weber S, et al. Psychiatric complications of levodopa therapy of Parkinson's disease. Adv Neurol 1984; 40: 271-7
7. Friedman JH. The management of the levodopa psychoses. Clin Neuropharmacol 1991; 14: 283:95
8. Moskovitz C, Moses III H, Klawans HL. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 1978; 135 (6): 669-75
9. Birkmayer W, Riederer P. Responsibility of extrastriatal areas for the appearance of psychotic symptoms: clinical and biochemical human post-mortem findings. J Neural Transm 1975; 137: 175-82
10. Mohr E, Mendis T, Grimes JD. Late cognitive changes in Parkinson's disease with an emphasis on dementia. In: Weiner WJ, Lang AE, editors. Advances in neurology. Vol. 65. Behavioral neurology of movement disorders. New York: Raven Press Ltd., 1995: 97-113
11. Mayeux R. Parkinson's disease: a review of cognitive and psychiatric disorders. Neuropsychiatr Neuropsychol Behav Neurol 1990; 3: 3-14
12. Lang AE, Johnson K. Akathisia in idiopathic Parkinson's disease. Neurology 1987; 37: 477-81
13. Lang AE. Akathisia and the restless legs syndrome. In: Jankovic J, Tolosa E, editors. Parkinson's disease and movement disorders. Baltimore (MD): Williams & Wilkins, 1993; 399-418
14. Comella CL, Goetz CG. Akathisia in Parkinson's disease. Mov Disord 1994; 9 (5): 545-9
15. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98
16. De Smet Y, Ruberg M, Serdaru M, et al. Confusion, dementia and anticholinergics in Parkinson's disease. J Neurol Neurosurg Psychiatry 1982; 45: 1161-4
17. Timberlake WH, Vance MA. Four year treatment of patients with parkinsonism using amantadine alone or with levodopa. Ann Neurol 1978; 3: 119-28
18. Tanner CM, Vogel C, Goetz CG, et al. Hallucinations in Parkinson's disease: a population study [abstract]. Ann Neurol 1983; 14 (1): 136
19. Friedman A, Sienkiewicz J. Psychotic complications of long-term levodopa treatment of Parkinson's disease. Acta Neurol Scand 1991; 84: 111-3
20. Friedman A. Old-onset Parkinson's disease compared with young-onset disease: clinical differences and similarities. Acta Neurol Scand 1994; 89: 258-61
21. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993; 43: 2227-9
22. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995; 45: 669-71
23. Porteons HB, Ross DN. Mental symptoms in parkinsonism following benzhexol hydrochloride therapy. BMJ 1956; 2: 138-40
24. Horrocks PM, Vicary DJ, Rees JE, et al. Anticholinergic withdrawal and benzhexol treatment in Parkinson's disease. J Neurol Neurosurg Psychiatry 1973; 36: 936-41
25. Doshay LJ. Five-year study of benztropine (Cogentin) methanesulfonate: outcome in three hundred two cases of paralysis agitans. JAMA 1956; 162: 1031-4
26. Whyte RK, Hunter KR, Laurence DR, et al. Levodopa and orphenadrine hydrochloride in parkinsonism. Eur J Clin Pharmacol 1971; 4: 18-21
27. Dubois B, Pillon B, Lhermitte F, et al. Cholineigic deficiency and frontal dysfunction in Parkinsou's disease. Ann Neurol 1990; 28: 117-21
28. Miller E, Berrios GE, Politynska B. The adverse effect of benzhexol on memory in Parkinson's disease. Acta Neurol Scand 1987; 76: 278-82
29. Koller WC. Disturbance of recent memory function in parkinsonian patients on anticholinergic therapy. Cortex 1984; 20: 307-11
30. van Spaendonck KPM, Berger HJC, Horstink MWI, et al. Impaired cognitive shifting in parkinsonian patients on anticholinergic therapy. Neuropsychologia 1993; 31 (4): 407-11
31. Taylor AE, Lang AE, Saint-Cyr JA, et al. Cognitive processes in idiopathic dystonia treated with high-dose anticholinergic therapy: implications for treatment strategies. Clin Neuropharmacol 1991; 14 (1): 62-77
32. Coid J, Strang J. Mania secondary to procyclidine ('Kemadrin') abuse. Br J Psychiatry 1982; 141: 81-4
33. Kaminer Y, Munitz H, Wijsenbeek H. Trihexyphenidyl (Artane) abuse: euphoriant and anxiolytic. Br J Psychiatry 1982; 140: 473-4
34. Doshay LJ, Constable K. Treatment of paralysis agitans with orphenadrine (Disipal) hydrochloride: results in one hundred seventy-six cases. JAMA 1957; 163 (15): 1352-7
35. Oertel WH, Dodel RC. International guide to drugs for Parkinson's disease. Mov Disord 1995; 10 (2): 121-31
36. Kornhuber J, Weller M. Amantadine and the glutamate hypothesis of schizophrenia: experiences in the treatment of neuroleptic malignant syndrome. J Neural Transm 1993; 92: 57-65
37. Schwab RS, England Jr AC, Poskanzer DC, et al. Amantadine in the treatment of Parkinson's disease. JAMA 1969; 208 (7): 1168-70
38. Dallos V, Heathfield K, Stone P, et al. Use of amantadine in Parkinson's disease: results of a double-blind trial. BMJ 1970; 4: 24-6
39. Barbeau A, Mars H, Botez MI, et al. Amantadine-HCL (Symmetrel) in the management of Parkinson's disease: a double-blind cross-over study. Can Med Assoc J 1971; 105: 42-7
40. Schwab RS, Poskanzer DC, England Jr AC, et al. Amantadine in Parkinson's disease. JAMA 1972; 222 (7): 792-5
41. Walker JE, Albers JW, Tourtellotte WW, et al. A qualitative and quantitative evaluation of amantadine in the treatment of Parkinson's disease. J Chron Dis 1972; 25: 149-82
42. Shannon KM, Goetz CG, Carroll VS, et al. Amantadine and motor fluctuations in chronic Parkinson's disease. Clin Neuropharmacol 1987; 10 (6): 522-6
43. Harper RW, Knothe BUC. Coloured lilliputian hallucinations with amantadine. Med J Aust 1973; 1: 444-5
44. Postma JU, van Tilburg W. Visual hallucinations and delirium during treatment with amantadine (Symmetrel). J Am Geriatr Soc 1975; 23: 212-5
45. McNamara P, Durso R. Reversible pathologic jealousy (Othello syndrome) associated with amantadine. J Geriatr Psychiatry Neurol 1991; 4: 157-9
46. Millet VM, Dreisbach M, Bryson YJ. Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine. Antimicrob Agents Chemother 1982; 21 (1): 1-4
47. McEvoy JP, McCue M, Spring B, et al. Effects of amantadine and trihexyphenidyl on memory in elderly normal volunteers. Am J Psychiatry 1987; 144: 573-7
48. Silver H, Geraisy N. Effects of biperiden and amantadine on memory in medicated chronic schizophrenic patients: a double-blind cross-over study. Br J Psychiatry 1995; 166: 241-3
49. Müller HF, Dastoor DP, Klingner A, et al. Amantadine in senile dementia: electroencephalographic and clinical effects. J Am Geriatr Soc 1979; 27 (1): 9-16
50. Schinitsky MR. A potential treatment for Alzheimer's disease [letter]? J Am Geriatr Soc 1991; 39 (12): 1242-3
51. Vardi J, Streifler M. On the synchronizing effect of amantadine-l-hydrochloride (Symmetrel) on pathological EEG-activity. J Neural Transm 1975; 37: 73-80
52. Parkes JD, Zilkha KJ, Marsden P, et al. Amantadine dosage in treatment of Parkinson's disease. Lancet 1970 May 30; 1: 1130-3
53. Berger JR, Weiner WJ. Exacerbation of Parkinson's disease following the withdrawal of amantadine [letter]. Neurology 1985; 35 Suppl. 1: 200
54. Bower DJ, Chalasani P, Ammons JC. Withdrawal-induced neuroleptic malignant syndrome. Am J Psychiatry 1994; 151 (3): 451-2
55. Jenkins RB, Groh RH. Mental symptoms in parkinsonian patients treated with L-dopa. Lancet 1970 Jul 25; 11: 177-80
56. Celesia GG, Barr AN. Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neurol 1970; 23: 193-200
57. Chen E. Drug-induced koro in a non-Chinese man [letter]. Br J Psychiatry 1991; 158: 721
58. Bush DF, Liss CL, Morton A, et al. An open multicenter long-term treatment evaluation of Sinemet CR. Neurology 1989; 39 Suppl. 2: 101-4
59. Joseph CL, Siple J, McWhorter K, et al. Adverse reactions to controlled release levodopa/carbidopa in older persons: case reports. J Am Geriatr Soc 1995; 43: 47-50
60. Marsh GC, Morcham CM, Ansel R, et al. Levodopa's awakening effect on patients with parkinsonism. J Neurol Neurosurg Psychiatry 1971; 34: 209-18
61. Botez MI, Barbeau A. Neuropsychological findings in Parkinson's disease: a comparison between various tests during long-term L-dopa therapy. Int J Neurol 1975; 10: 222-32
62. Huber SJ, Shulman HG, Paulson GW, et al. Fluctuations in plasma dopamine level impair memory in Parkinson's disease. Neurology 1987; 37: 1371-5
63. Gotham AM, Brown RG, Marsden CD. 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain 1988; 111: 299-321
64. Comella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations. Ann Neurol 1993; 34: 710-4
65. Menza MA, Rosen RC. Sleep in Parkinson's disease: the role of depression and anxiety. Psychosomatics 1995; 36: 262-6
66. Nissenbaum H, Quinn NP, Brown RG, et al. Mood swings associated with the 'on-off' phenomenon in Parkinson's disease. Psychol Med 1987; 17: 899-904
67. Maricle RA, Nutt JG, Carter JH. Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion: preliminary findings. Mov Disord 1995; 10 (3): 329-32
68. Vázquez A, Jiménez-Jiménez, FJ, García-Ruiz P, et al. 'Panic attacks' in Parkinson's disease: a long-term complication of levodopa therapy. Acta Neurol Scand 1993; 87: 14-8
69. Calne DB, Leigh PN, Teychenne PF, et al. Treatment of parkinsonism with bromocriptine. Lancet 1974; 11: 1355-6
70. Jansen ENH, Meerwaldt JD. Long-term treatment with high-dosage bromocriptine in advanced Parkinson's disease. Adv Neurol 1986; 45: 539-42
71. Hoehn MMM, Elton RL. Low dosages of bromocriptine added to levodopa in Parkinson's disease. Neurology 1985; 35: 199-206
72. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet® in Parkinson's disease. Mov Disord 1994: 9 (1): 40-7
73. Factor SA, Weiner WJ. Early combination therapy with bromocriptine and levodopa in Parkinson's disease. Mov Disord 1993; 8 (3): 257-62
74. Stern Y, Mayeux R, Ilson J, et al. Pergolide therapy for Parkinson's disease: neurobehavioral changes. Neurology 1984; 34: 201-4
75. Stocchi F, Bramante L, Monge A, et al. Apomorphine and lisuride infusion: a comparative chronic study. Adv Neurol 1993; 60: 653-5
76. Quinn NP, Lang AE, Thompson C, et al. Pergolide in the treatment of Parkinson's disease. Adv Neurol 1984; 40: 509-13
77. Thompson C. Anwesenheit: psychopathology and clinical associations. Br J Psychiatry 1982; 141: 628-30
78. Tanner CM, Goetz CG, Glantz RH, et al. Pergolide mesylate: four years experience in Parkinson's disease. Adv Neurol 1986; 45: 547-9
79. Lieberman A, Kupersmith M, Estey E, et al. Treatment of Parkinson's disease with bromocriptine. N Engl J Med 1976; 295: 1400-4
80. Lieberman A. Bromocriptine in Parkinson's disease. In: Koller WC, Paulson G, editors. Therapy of Parkinson's disease. New York: Marcel Dekker, Inc., 1990: 255-67
81. Lieberman AN, Gopinathan G, Neophytides A, et al. Pergolide and lisuride in advanced Parkinson's disease. Adv Neurol 1984; 40: 503-7
82. Pezzoli G, Martignoni E, Pacchetti C, et al. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study. Mov Disord 1994; 9 (4): 431-6
83. LeWitt PA, Ward CD, Larsen TA, et al. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology 1983; 33: 1009-14
84. Laihinen A, Rinne UK, Suchy I. Comparison of lisuride and bromocriptine in the treatment of advanced Parkinson's disease. Acta Neurol Scand 1992; 86: 593-5
85. Pezzoli G, Martignoni E, Pacchetti C, et al. A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease. Neurology 1995; 45 Suppl. 3: S22-7
86. Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology 1995; 45 Suppl. 3: S13-21
87. Vaamonde J, Luquin MR, Obeso JA. Subcutaneous lisuride infusion in Parkinson's disease. Brain 1991; 114: 601-14
88. Kempster PA, Iansek R, Larmour I. Intermittent subcutaneous apomorphine injection treatment for parkinsonian motor oscillations. Aust N Z J Med 1991; 21: 314-8
89. Corboy DL, Wagner ML, Sage JI. Apomorphine for motor fluctuations and freezing in Parkinson's disease. Ann Pharmacother 1995; 29: 282-8
90. Tolosa E, Balaguer E, Ribera G. Continuous infusion of subcutaneous (s.c.) lisuride (LS) for levodopa-related motor fluctuations (LRMF): long-term follow-up [letter]. Neurology 1989; 39 Suppl. 1: 340
91. Allain H, Pollak P, Neukirch HC, et al. Symptomatic effect of selegiline in de novo parkinsonian patients. Mov Disord 1993; 8 (1 Suppl.): S36-40
92. Brannan T, Yahr MD. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease. Ann Neurol 1995; 37: 95-8
93. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995; 38: 771-7
94. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996; 39: 37-45
95. Teychenne PF, Parker S. Double-blind, crossover placebo controlled trial of selegiline in Parkinson's disease - an interim analysis. Acta Neurol Scand 1989; 126: 119-25
96. Heinonen EH, Rinne UK, Tuominen J. Selegiline in the treatment of daily fluctuations in disability of parkinsonian patients with long-term levodopa treatment. Acta Neurol Scand 1989; 126: 113-8
97. Dalrymple-Alford JC, Jamieson CF, Donaldson IM. Effects of selegiline (deprenyl) on cognition in early Parkinson's disease. Clin Neuropharmacol 1995; 18 (4): 348-59
98. Lieberman AN, Gopinathan G, Neophytides A, et al. Deprenyl versus placebo in Parkinson disease: a double-blind study. N Y State J Med 1987; 87: 646-9
99. Boyson SJ. Psychiatric effects of selegiline [letter]. Arch Neurol 1991; 48: 902
100. Yahr MD, Mendoza MR, Moros D, et al. Treatment of Parkinson's disease in early and late phases: use of pharmacological agents with special reference to deprenyl (selegiline). Acta Neurol Scand 1983; 68 Suppl. 95: 95-102
101. Uitti RJ, Tanner CM, Rajput AH, et al. Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol 1989; 12 (5): 375-83
102. Kurlan R, Dimitsopulos T. Selegiline and manic behavior in Parkinson's disease [letter]. Arch Neurol 1992; 49: 1231
103. Suchowersky O, deVries J. Possible interactions between deprenyl and Prozac. Can J Neurol Sci 1990; 17 (3): 352-3
104. Montastruc JL, Chamontin B, Senard JM, et al. Pseudo-phaeochromocytoma in parkinsonian patient treated with fluoxetine plus selegiline [letter]. Lancet 1993; 341: 555
105. Lefebvre H, Noblet C, Moore N, et al. Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline. Clin Endocrinol 1995; 42: 95-9
106. Zornberg GL, Bodkin JA, Cohen BM. Severe adverse interaction between pethidine and selegiline [letter]. Lancet 1991; 337: 246
107. Golbe LI. Deprenyl as symptomatic therapy in Parkinson's disease. Clin Neuropharmacol 1988; 11 (5): 387-400
108. Lang AE. Clinical rating scales and videotape analysis. In: Koller WC, Paulson G, editors. Therapy of Parkinson's disease. New York: Marcel Dekker, Inc., 1990: 3-30
109. Levin BE, Llabre MM, Weiner WJ. Parkinson's disease and depression: psychometric properties of the Beck Depression Inventory. J Neurol Neurosurg Psychiatry 1988; 51: 1401-4
110. Goetz CG, Tanner CM, Klawans HL. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry 1982; 139: 494-7
111. Saint-Cyr JA, Taylor AH, Lang AE. Neuropsychological and psychiatric side effects in the treatment of Parkinson's disease. Neurology 1993; 43 Suppl. 6: S47-52
112. Koller WC. Pharmacologic treatment of parkinsonian tremor. Arch Neurol 1986; 43: 126-7
113. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment resistant schizophrenic: a double-blind comparison. Arch Gen Psychiatry 1988; 45: 789-96
114. Casey DE. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 1989; 99: S47-53
115. Pfeiffer RF, Kang J, Graber B, et al. Clozapine for psychosis in Parkinson's disease. Mov Disord 1990; 5: 239-42
116. Wolters EC, Hurwitz TA, Mak E, et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 1990; 40: 832-4
117. Factor SA, Brown D. Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov Disord 1992; 7 (2): 125-31
118. Friedman JH, Lannon MC. Clozapine-responsive tremor in Parkinson's disease. Mov Disord 1990; 5: 225-9
119. Roberts HE, Dean RC, Stoudemire A. Clozapine treatment of psychosis in Parkinson's disease. J Neuropsychiatry 1989; 1: 190-2
120. Bennett Jr JP, Landow ER, Dietrich S, et al. Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction. Mov Disord 1994; 9 (4): 409-14
121. Linazusoro G, Suarez JA, Marti Masso JF. Clozapine in Parkinson's disease: three years' experience [abstract]. Mov Disord 1992; 7 Suppl.: 100
122. Friedman JH, Lannon MC. Clozapine in the treatment of psychosis in Parkinson's disease. Neurology 1989; 39; 1219-21
123. Greene P, Cote L, Fahn S. Treatment of drug-induced psychosis in Parkinson's disease with clozapine. Adv Neurol 1993; 60: 703-6
124. Factor SA, Molho ES, Podskalny GD, et al. Parkinson's disease: drug-induced psychiatric states. In: Weiner WJ, Lang AE, editors. Advances in neurology. Vol. 65. Behavioral neurology of movement disorders. New York: Raven Press Ltd., 1995: 115-50
125. Friedman JH, Lannon MC, Caley C. Clozapine for movement disorder patients: a retrospective analysis of 38 patients [abstract]. Ann Neurol 1992; 32: 277
126. Lew MF, Waters CH. Clozapine treatment of parkinsonism with psychosis. J Am Geriatr Soc 1993; 41: 669-71
127. Meltzer HY, Kennedy J, Dai J, et al. Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease: a high potency effect of clozapine. Neuropsychopharmacology 1995; 12 (1): 39-45
128. Scholz E, Dichgans J. Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatry Neurol Sci 1985; 235: 60-4
129. Rabey JM, Treves TA, Neufeld MY, et al. Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease. Neurology 1995; 45: 432-4
130. Factor SA, Brown O, Molho ES, et al. Clozapine: a two year open trial in Parkinson's disease patients with psychosis. Neurology 1994; 44: 544-6
131. Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991; 17: 263-87
132. Meco G, Alessandria A, Bonifati V, et al. Risperidone for hallucinations in levodopa-treated Parkinson's disease patients [letter]. Lancet 1994; 343: 1370
133. Ford B, Lynch T, Greene P. Risperidone in Parkinson's disease [letter]. Lancet 1994; 344: 681
134. Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995; 56: 556-9
135. Mendis T, Mohr E, George A, et al. Symptomatic relief from treatment-induced psychosis in Parkinson's disease: an open-label pilot study with remoxipride. Mov Disord 1994; 9 (2): 197-200
136. Lang AE, Sandor P, Duff J. Remoxipride in Parkinson's disease: differential response in patients with dyskinesia fluctuations versus psychosis. Clin Neuropharmacol 1995; 18 (1): 39-44
137. Arnold G, Trenkwalder C, Schwartz J, et al. Zotepine reversibly induces akinesia and rigidity in Parkinson's disease patients with resting tremor or drug induced psychosis. Mov Disord 1994; 9 (2): 238-40
138. Spieker S, Stetter F, Klockgether T. Zotepine m levodopa-induced psychosis [editorial]. Mov Disord 1995; 10: 795-6
139. Zoldan J, Friedberg G, Goldberg-Stern H, et al. Ondansetron for hallucinosis in advanced Parkinson's disease. Lancet 1993; 341: 562-3
140. Ikeguchi K, Kuroda A. Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs. Eur Arch Psychiatry Clin Neurosci 1995; 244 (6): 320-4
141. White A, Corn TH, Feetham C. Ondansetron in treatment of schizophrenia [letter]. Lancet 1991; 337: 1173
142. Zoldan J, Friedberg G, Livneh M, et al. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 1995; 45: 1305-8
143. Halperin JR, Murphy B. Extrapyramidal reaction to ondansetron [letter]. Cancer 1992; 69: 1275
144. Douyon R, Serby M, Klutchko B, et al. ECT and Parkinson's disease revisited: a 'naturalistic' study. Am J Psychiatry 1989; 146 (11): 1451-5
145. Kellner CH, Beale MD, Pritchett JT, et al. Electroconvulsive therapy and Parkinson's disease: the case for further study. Psychopharmacol Bull 1994; 30 (3): 495-500.
146. Hurwitz TA, Calne DB, Waterman K. Treatment of dopaminomimetic psychosis in Parkinson's disease with electroconvulsive therapy. Can J Neurol Sci 1988; 15: 32-4
147. Oh JJ, Rummans TA, O'Connor MK, et al. Cognitive impairment after ECT in patients with Parkinson's disease and psychiatric illness [letter]. Am J Psychiatry 1992; 149 (2): 271
148. Figiel GS, Hassen MA, Zorumski C, et al. ECT-induced delirium in depressed patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 1991; 3: 405-11
149. Figiel GS. Cognitive impairment after ECT in patients with Parkinson's disease and psychiatric illness: reply [letter]. Am J Psychiatry 1992; 149 (12): 1759
150. Rasmussen K, Abrams R. Treatment of Parkinson's disease with electroconvulsive therapy. Psychiatr Clin North Am 1991; 14 (4): 925-33
151. Weiner WJ, Koller WC, Perlik S, et al. Drug holiday and management of Parkinson disease. Neurology 1980; 30: 1257-61
152. Direnfeld LK, Feldman RG, Alexander MP, et al. Is L-DOPA drug holiday useful? Neurology 1980; 30: 785-8
153. Kaye JA, Feldman RG. The role of L-DOPA holiday in the long-term management of Parkinson's disease. Clin Neuiopharmacol 1986; 9 (1): 1-13